A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin
Intravenous immunoglobulins (IVIGs) were initially designed to treat patients with primary immunodeficiencies (PID). Due to the multidirectional effect of IVIGs on the immune system, a range of nosological entities, in which these agents are successfully administered, is steadily expanding. As of no...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
"Consilium Medicum" Publishing house
2016-04-01
|
| Col·lecció: | Терапевтический архив |
| Matèries: | |
| Accés en línia: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31987/pdf |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|